Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA May Ask HRA For Another OTC Birth Control Actual Use Study Due To ‘Improbable Dosing’

May 08 2023

• By Malcolm Spicer

• Source: Shutterstock

Related Content

US FDA Requests More Information, Needs More Time To Review Birth Control OTC Switch Proposal

Oct 27 2022

US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application

Jul 12 2022

HRA Pharma And Maxwellia To Launch The UK’s First OTC Daily Contraceptives

Jul 09 2021

‘Over-Reporting’ An ‘Inherent Risk’ In Self-Report Study – Oral Contraceptive OTC Switch Sponsor

May 08 2023

Related Companies

Perrigo Company PLC

Additional Topics

International United States Clinical Trials FDA Prescription To OTC Switch Advertising, Marketing & Sales Business Strategies Commercial Companies Compliance Consumer Drug Approval Standards Drug Review Drug Safety Ingredients Manufacturing OTC Drugs Policy Politics Regulation Safety Gynecology & Urology

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window